Luiz Eduardo Fonteles Ritt, Pedro Gabriel Melo de Barros E Silva, Eduardo Sahade Darzé, Renato Hideo Nakagawa Santos, Queila Borges de Oliveira, Otavio Berwanger, Luiz Alberto Piva E Mattos, Elizabete Silva Dos Santos, Antonio Carlos Sobral Souza, Margaret Assad Cavalcante, Pedro Beraldo de Andrade, Fernando Carvalho Neuenschwander, Hugo Vargas Filho, Jorge Ilha Guimarães, Jadelson Pinheiro de Andrade, Angelo Amato Vincenzo de Paola, Marcus Vinícius Bolívar Malachias, Dalton Bertolim Précoma, Fernando Bacal, Oscar Pereira Dutra
{"title":"Myocardial Infarction with ST Elevation and Reperfusion Therapy in Brazil: Data from the ACCEPT Registry.","authors":"Luiz Eduardo Fonteles Ritt, Pedro Gabriel Melo de Barros E Silva, Eduardo Sahade Darzé, Renato Hideo Nakagawa Santos, Queila Borges de Oliveira, Otavio Berwanger, Luiz Alberto Piva E Mattos, Elizabete Silva Dos Santos, Antonio Carlos Sobral Souza, Margaret Assad Cavalcante, Pedro Beraldo de Andrade, Fernando Carvalho Neuenschwander, Hugo Vargas Filho, Jorge Ilha Guimarães, Jadelson Pinheiro de Andrade, Angelo Amato Vincenzo de Paola, Marcus Vinícius Bolívar Malachias, Dalton Bertolim Précoma, Fernando Bacal, Oscar Pereira Dutra","doi":"10.36660/abc.20230863","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is a lack of information from Brazil regarding therapies used and outcomes in patients with acute coronary syndrome with ST elevation (STEMI).</p><p><strong>Objectives: </strong>To evaluate evidence-based therapies, occurrence of outcomes, reperfusion use, and predictors of not receiving reperfusion in patients with STEMI in a national multicenter registry.</p><p><strong>Methods: </strong>Patients with STEMI from the ACCEPT registry, with up to 12 hours of symptoms, were followed for 1 year for the occurrence of major adverse cardiovascular events. A significance level of p < 0.05 was applied for all analyses.</p><p><strong>Results: </strong>In the analysis of 1553 patients, the reperfusion rate was 76.8%, ranging from 47.5% in the North Region to 80.5% in the Southeast Region. The rate of major adverse cardiovascular events was 12.5% at 1 year. The prescription of evidence-based therapies at hospital admission was 65.6%. The presence of hypertension (odds ratio [OR] 1.47; 95% confidence interval [CI] 1.11 to 1.96; p < 0.01); prior acute myocardial infarction (OR 1.81; 95% CI 1.32 to 2.48; p < 0.001); and the North (OR 4.65; 95% CI 2.87 to 7.52; p < 0.001), Central-West (OR 4.02; 95% CI 1.26 to 12.7; p < 0.05), and Northeast Regions (OR 1.70; 95% CI 1.17 to 2.46; p < 0.01) were independent predictors of not receiving reperfusion therapy.</p><p><strong>Conclusion: </strong>In the 1-year follow-up of the ACCEPT Registry, we were able to verify a wide variation within Brazilian geographical regions regarding adherence to best care practices. The following were independent predictors of not receiving reperfusion therapy: being treated in the North, Central-West, and Northeast Regions; having systemic arterial hypertension; and prior infarction.</p>","PeriodicalId":93887,"journal":{"name":"Arquivos brasileiros de cardiologia","volume":"121 11","pages":"e20230863"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11634312/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arquivos brasileiros de cardiologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36660/abc.20230863","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: There is a lack of information from Brazil regarding therapies used and outcomes in patients with acute coronary syndrome with ST elevation (STEMI).
Objectives: To evaluate evidence-based therapies, occurrence of outcomes, reperfusion use, and predictors of not receiving reperfusion in patients with STEMI in a national multicenter registry.
Methods: Patients with STEMI from the ACCEPT registry, with up to 12 hours of symptoms, were followed for 1 year for the occurrence of major adverse cardiovascular events. A significance level of p < 0.05 was applied for all analyses.
Results: In the analysis of 1553 patients, the reperfusion rate was 76.8%, ranging from 47.5% in the North Region to 80.5% in the Southeast Region. The rate of major adverse cardiovascular events was 12.5% at 1 year. The prescription of evidence-based therapies at hospital admission was 65.6%. The presence of hypertension (odds ratio [OR] 1.47; 95% confidence interval [CI] 1.11 to 1.96; p < 0.01); prior acute myocardial infarction (OR 1.81; 95% CI 1.32 to 2.48; p < 0.001); and the North (OR 4.65; 95% CI 2.87 to 7.52; p < 0.001), Central-West (OR 4.02; 95% CI 1.26 to 12.7; p < 0.05), and Northeast Regions (OR 1.70; 95% CI 1.17 to 2.46; p < 0.01) were independent predictors of not receiving reperfusion therapy.
Conclusion: In the 1-year follow-up of the ACCEPT Registry, we were able to verify a wide variation within Brazilian geographical regions regarding adherence to best care practices. The following were independent predictors of not receiving reperfusion therapy: being treated in the North, Central-West, and Northeast Regions; having systemic arterial hypertension; and prior infarction.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
